Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4a3309a45498656353176c062b359aa3 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
filingDate |
2008-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1bd2fb268e5d6602f15d9ba265301fe2 |
publicationDate |
2010-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-2195024-A1 |
titleOfInvention |
Method of inhibiting complement activation with factor bb specific antibodies |
abstract |
A process of inhibiting the adverse effects of alternative complement pathway activation products in a subject includes administering to the subject an amount of anti-factor Bb antibody effective to selectively inhibit formation of an alternative complement pathway activation products C3a, C5a, and C5b-9, and activation of neutrophils, monocytes, and platelets. |
priorityDate |
2007-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |